-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $16

Benzinga·09/03/2026 11:44:27
语音播报
Baird analyst Joel Beatty downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Outperform to Neutral and lowers the price target from $40 to $16.